Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
University of Florida
Emory University
Children's Oncology Group
Novartis
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Hospital Los Angeles
Baylor College of Medicine
St. Jude Children's Research Hospital
Children's Oncology Group
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Hoffmann-La Roche
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
St. Jude Children's Research Hospital
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
University Hospital Southampton NHS Foundation Trust
Baylor College of Medicine
Dana-Farber Cancer Institute
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
British Columbia Cancer Agency
Memorial Sloan Kettering Cancer Center
Seattle Children's Hospital
Instituto do Cancer do Estado de São Paulo
Nationwide Children's Hospital
Baylor College of Medicine
New Approaches to Neuroblastoma Therapy Consortium
New Approaches to Neuroblastoma Therapy Consortium
Bambino Gesù Hospital and Research Institute
Pfizer
University of Birmingham